MYD88 and rheumatoid arthritis: Several antagonists targeting TLR-MyD88 signaling have been shown to have a therapeutic effect on preclinical models of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, and colitis (Christensen et al., 2006; Schmidt, 2006).